Business
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company’s innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management. These two clearances mark an important step forward for Bioventus and represent a substantial growth oppor
About this update from Bioventus Inc.
[{"type":"image","alt":"Bioventus, Inc.","displaySize":"","headline":null,"caption":"Bioventus, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qQ49MJubWbfvVwM2vqI94Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302","width":300,"height":55}},"lazy":false},{"type":"text","content":"DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company’s innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management.","length":393,"tagName":"p"},{"type":"text","content":"These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann™ and StimTrial™ now FDA-cleared, Bioventus offers a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility. This development also reinforces the Company’s commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs.","length":694,"tagName":"p"},{"type":"text","content":"“The FDA clearance of both TalisMann™ and StimTrial™ represents a significant step forward in our PNS business, providing patients with innovative technologies. It also creates an exciting growth opportunity for our business”, said Anthony Doyle, General Manager, Pain and Restorative Therapies of Bioventus.","length":308,"tagName":"p"},{"type":"text","content":"Portfolio Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TalisMann™: Combines our patented electric field conduction technology with an integrated pulse generator to potentially reach deeper, larger nerves. This combination is designed ...